Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10646367 | 0.98 | HPGD (0.57) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL2044935 | 0.94 | KIF11 (0.59) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL3555520 | 0.89 | KDM4E (0.59) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL10417625 | 0.88 | HPGD (0.56) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL3019804 | 0.87 | PTPN11 (0.50) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL13157249 | 0.87 | NPC1 (0.59) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL3555970 | 0.85 | NPC1 (0.61) | HPGDRECQLLMNASMN1; SMN2PGR | |
| SCHEMBL4624606 | 0.83 | HPGD (0.64) | KEAP1HPGDPTGS2RECQLKMT2A | |
| SCHEMBL7745099 | 0.83 | HPGD (0.59) | KEAP1HPGDPTGS2RECQLCA12 | |
| SCHEMBL25232308 | 0.83 | XDH (0.57) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | claimed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | claimed |
| EP-4743457-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-12383560-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-4522917-A | STORAGE STABLE; CONTROLLED RELEASE DURING DEVELOPMENT | FUJI PHOTO FILM CO., LTD. (JP) | 1985-06-11 | — | — | US | disclosed |
| US-4482566-A | ANTIULCER AGENTS | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1984-11-13 | — | — | US | disclosed |
| EP-0023578-B1 | AMINOALKYLBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | SHIONOGI & CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4309433-A | TREATMENT OF PEPTIC ULCERS | SHIONOGI & CO., LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| EP-0023578-A1 | Aminoalkylbenzene derivatives, process for their preparation and pharmaceutical compositions | SHIONOGI & CO., LTD. (JP) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383560-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | KEAP1 1241/4885HPGD 3705/4885PTGS2 4716/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | KEAP1 3969/4885HPGD 1182/4885PTGS2 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.